Amaranth Medical Completes MEND-II and RENASCENT Studies and Initiates Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold
15 oct. 2015 08h00 HE
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Oct. 15, 2015 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, announced that enrollment has successfully concluded in its multi-center, international...
Amaranth Medical Reports Findings from Two FORTITUDE Bioresorbable Scaffold Studies at EuroPCR 2015
18 mai 2015 15h12 HE
|
Amaranth Medical, Inc.
Mountain View, CA, May 18, 2015 (GLOBE NEWSWIRE) -- Amaranth Medical, a
privately held medical device company, announced plans to report
clinical results from the Company's ongoing trial of...
TissueGen Enhances Intellectual Property Portfolio With New Patent for Self-Expanding Medical Device
29 avr. 2014 10h00 HE
|
TissueGen Inc.
DALLAS, TX--(Marketwired - Apr 29, 2014) - TissueGen® Inc., developer of cutting-edge biodegradable polymer technology for implantable drug delivery across a wide variety of therapeutic...
VENITI, Inc. Announces First Uses of Veniti Vici Venous Stent System
23 janv. 2014 17h07 HE
|
VENITI, Inc.
ST. LOUIS, Jan. 23, 2014 (GLOBE NEWSWIRE) -- VENITI announced today that patients in the European Union (EU) were successfully treated for symptomatic venous outflow obstruction of the lower...
Amaranth Medical Announces Investment from Boston Scientific
14 janv. 2014 09h14 HE
|
Amaranth Medical, Inc.
Mountain View, CA, Jan. 14, 2014 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, today
announced the closing of an equity investment by Boston Scientific
Corporation...
2012 Deep Research Report on Global and China Coronary Stent Industry
12 nov. 2013 09h19 HE
|
Research and Markets
Dublin, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/zt55qc/2012_deep)
has announced the addition of the "2012
Deep Research Report on Global and...
Amaranth Medical Reports Positive Safety and Feasibility Findings for the FORTITUDE(TM) Bioresorbable Scaffold
28 oct. 2013 08h00 HE
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company,
presented positive six-month angiographic results from its
first-in-human study...
Amaranth Medical Raises $20 Million in Series B to Support Development of the FORTITUDE(tm) Bioresorbable Scaffold
07 oct. 2013 20h00 HE
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Oct. 7, 2013 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company,
announced the closing of a $20 million Series B financing led by
new investor DCP...
Alameda County Medical Center Earns Important Cardiac Designation
11 déc. 2012 13h30 HE
|
Alameda Health System
OAKLAND, Calif., Dec. 11, 2012 (GLOBE NEWSWIRE) -- Alameda County Medical Center (ACMC www.acmedctr.org), a leading public health care provider, was designated a STEMI Receiving Center (SRC) and...
Biodegradable Stent Safe for Long-Term Treatment of Coronary Artery Disease
16 avr. 2012 16h00 HE
|
American Heart Association
Study Highlights:
The first fully biodegradable stent inserted into humans proved safe in a 10-year study.
Major cardiac complication rates were similar to rates of non-biodegradable stents...